Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
about
Interaction of Isoflavones with the BCRP/ABCG2 Drug TransporterThe FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactionsBCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenibEffect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell LinesIdentification of ABC Transporter Interaction of a Novel Cyanoquinoline Radiotracer and Implications for Tumour Imaging by Positron Emission TomographyEGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML).P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patientsIdentification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay.Identification and functional characterization of breast cancer resistance protein in human bronchial epithelial cells (Calu-3).Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapiesInhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.Drug resistance in cancer: an overview.Substrate affinity of photosensitizers derived from chlorophyll-a: the ABCG2 transporter affects the phototoxic response of side population stem cell-like cancer cells to photodynamic therapy.Modification of topoisomerases in mammospheres derived from breast cancer cell line: clinical implications for combined treatments with tyrosine kinase inhibitors.Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance proteinA single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2).The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitorsReversing multidrug resistance by tyrosine kinase inhibitorsThe Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanismsCancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma.Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics.Nanoformulations for combination or cascade anticancer therapy.GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance.Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib.Synthetic Analogs of Curcumin Modulate the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCG2.
P2860
Q26801110-5EC6E66C-D55D-4A06-96D7-2EB5D21FC632Q28535342-D6111D78-2895-496F-B57D-39C355CB1D50Q28538126-686E66B9-B1BF-42A0-9767-FCEF01B877CDQ28550693-5E5C8328-1D85-4530-8F80-D1D3C77C8104Q28553692-116FCDA9-B136-4CC7-ADE1-F4F45AE2127AQ30456087-46E08B14-439A-43D9-B0C2-D18BC25C069BQ33319637-DF2382A4-1F4A-480F-90F4-249253563D62Q33472987-C4442985-F26F-4372-803D-B9E7EF3453D5Q33476723-5DD141A4-A6A6-4CC1-A830-149880138665Q33506860-FC348B6D-B144-468F-8FCE-37E6A5D97D63Q33566582-4D15096F-8048-4BE0-AF28-B6D36018BFCEQ33730375-0B27BA4C-1864-4B7D-9188-F8B4D43800EEQ33746958-E889BBB2-EE1A-4FDC-A58D-508D11B9997FQ33753716-106F072D-1BB6-4184-8DC9-1226BADD5D8AQ34437369-1D6AAE0D-C3F1-4FA5-9472-2EC9269C5703Q34472249-9778149E-E348-47A5-8FC7-CEF9F2B73EE1Q34896154-B748B21F-EAA1-4278-ABD7-B35488C2A38EQ35033091-677F7628-754D-4EED-A095-A0214A9ED14CQ35597039-C7DE01BA-9F1D-4CEB-B184-E75F9CD348B0Q35708124-8D87AA42-F9DC-43B4-839A-D8F00D2C527BQ35946822-0BE825B7-7466-4584-8832-CA9775AB08BDQ36052743-86AC3EA5-2456-4427-9941-0060E7CF3552Q36933169-F518BC7A-1633-4071-8BB8-7452AC795EEDQ37078093-E741286E-D5BC-417A-AB25-696E5F1E197EQ37183670-AF71D09F-CE06-417D-97C6-D0074A7B1E1AQ37289700-EF661087-86AA-46BE-96E8-9B6F0437EFC3Q37316834-B46C6BC1-7318-440C-809A-2544DC431B82Q37958162-1445B9E1-DE9F-478A-A13D-AF6A16EFFB0CQ38187646-88096E81-C10E-4F96-A5F5-FE783C583C90Q39380111-197B7FF1-7153-4573-AEF1-FDDFA12508DFQ39380536-296D3EBD-25C1-4812-9E18-5A2C2A3B2176Q39874489-B1EDBD99-3873-4427-8A6F-9C95BA5AE838Q42703731-986897A1-8973-4329-8C3A-BB66C61159C7
P2860
Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
@en
type
label
Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
@en
prefLabel
Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
@en
P2093
P1476
Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
@en
P2093
Etsuko Ishikawa
Kae Yanase
Sakiyo Asada
Satomi Tsukahara
Yasuo Imai
Yoshikazu Sugimoto
P304
P577
2004-09-01T00:00:00Z